Compounds that inhibit pkmyt1

A compound according to Formula I:

• or a pharmaceutically acceptable salt thereof,
• wherein:
• each represents a single bond, a double bond, or a delocalized π bond;
• U is selected from the group consisting of N and CH;
• V is selected from the group consisting of C and N;
• W is selected from the group consisting of C and N;
• X is selected from the group consisting of N, NR3a, CR3, S, and O;
• Y is selected from the group consisting of CR4, N, NR4a, S, and O;
• Z is selected from the group consisting of CR5, N, NR5a, S, and O;
• ring A is
• 3- to 14-membered carbocyclyl substituted with 1, 2, 3, 4, or 5 R6, or
• 5- to 14-membered heterocyclyl comprising at least one oxygen atom, nitrogen atom, or sulfur atom, wherein the heterocyclyl is substituted with 0, 1, 2, 3, or 4 R6;
• R1 is selected from the group consisting of amino, hydroxy, and hydrogen;
• each R2 is independently selected from the group consisting of hydrogen and C1-6 alkyl;
• R3, R4, and R5 are independently selected from the group consisting of hydrogen, amino, hydroxy, halogen, cyano, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, —NO2, —CO(C1-6 alkyl), —COOH, —COO(C1-6 alkyl), —CON(R7)2, -L-(5- to 12-membered heterocyclyl), -L-(5- to 14-membered heteroaryl), and -L-(C6-14 aryl), wherein the 5- to 12-membered heterocyclyl, 5- to 14-membered heteroaryl, and C6-14 aryl are independently substituted with 0, 1, 2, 3, or 4 R6;
• each L is independently selected from the group consisting of a covalent bond, —O—, C1-6 alkylene, and NRa;
• any two adjacent R3, R4, and R5 are optionally taken together with the carbon atoms to which they are attached to form a 5- or 6-membered carbocyle or heterocycle, each of which is optionally substituted with 0, 1, 2, 3, or 4 R6;
• R3a, R4a, R5a, and R7 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-8 cycloalkyl, -L-(5- to 12-membered heterocyclyl), -L-(5- to 14-membered heteroaryl, and -L-(C6-14 aryl), wherein the C3-8 cycloalkyl, 5- to 12-membered heterocyclyl, 5- to 14-membered heteroaryl, and C6-14 aryl are independently substituted with 0, 1, 2, 3, or 4 R6;
• each R6 is independently selected from the group consisting of hydroxy, amino, cyano, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, oxo, —NO2, —CHO, —CO(C1-6 alkyl), —COORa, —CON(Ra)2, —SO2(C1-6 alkyl), and —SO2N(Ra)2;
• and
• each Ra is independently selected from the group consisting of hydrogen, C1-6 alkyl, and C1-6 haloalkyl;
• provided that ring A is substituted with at least one R6 that is selected from the group consisting of hydroxy, amino, cyano, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, oxo, —NO2, —CHO, —CO(C1-6 alkyl), —COORa, —CON(Ra)2, and —SO2N(Ra)2 when ring A is a carbocycle and R1 and each R2 are hydrogen;
• and
• provided that ring A is substituted with at least one R6 that is selected from the group consisting of hydroxy, amino, cyano, halogen, C1-6 haloalkyl, C1-6 hydroxyalkyl, oxo, —NO2, —CHO, —CO(C1-6 alkyl), —COORa, —CON(Ra)2, —SO2(C1-6 alkyl), and —SO2N(Ra)2 when ring A is a heterocycle and R1 and each R2 are hydrogen.